➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
AstraZeneca
Harvard Business School
Colorcon
Mallinckrodt

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CASODEX

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

505(b)(2) Clinical Trials for Casodex

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01416870 ↗ Bioequivalence of Bicalutamide New Formulation in Japan Terminated AstraZeneca Phase 1 2010-07-01 The purpose of this study is to investigate the bioequivalence of Bicalutamide new formation with Casodex commercial tablet (80mg) in Japanese healthy male subjects
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Casodex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002874 ↗ Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer Active, not recruiting National Cancer Institute (NCI) Phase 3 1998-02-01 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II, stage III, or recurrent prostate cancer and elevated PSA levels following radical prostatectomy.
NCT00002874 ↗ Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer Active, not recruiting NRG Oncology Phase 3 1998-02-01 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II, stage III, or recurrent prostate cancer and elevated PSA levels following radical prostatectomy.
NCT00002874 ↗ Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer Active, not recruiting Southwest Oncology Group Phase 3 1998-02-01 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II, stage III, or recurrent prostate cancer and elevated PSA levels following radical prostatectomy.
NCT00002874 ↗ Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer Active, not recruiting Radiation Therapy Oncology Group Phase 3 1998-02-01 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II, stage III, or recurrent prostate cancer and elevated PSA levels following radical prostatectomy.
NCT00003026 ↗ Hormone Therapy in Treating Patients With Advanced Prostate Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1997-04-01 RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase III trial to compare the effectiveness of long-term hormone therapy and triptorelin with no further treatment in treating patients who have advanced prostate cancer previously treated with radiation therapy and 6 months of androgen suppression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Casodex

Condition Name

Condition Name for Casodex
Intervention Trials
Prostate Cancer 32
Healthy 5
Adenocarcinoma of the Prostate 3
Stage IVA Prostate Cancer AJCC v8 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Casodex
Intervention Trials
Prostatic Neoplasms 41
Adenocarcinoma 5
Hirsutism 2
Gynecomastia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Casodex

Trials by Country

Trials by Country for Casodex
Location Trials
United States 132
Italy 26
Canada 24
United Kingdom 11
Spain 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Casodex
Location Trials
Texas 9
California 6
Massachusetts 6
New York 5
Maryland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Casodex

Clinical Trial Phase

Clinical Trial Phase for Casodex
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2 18
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Casodex
Clinical Trial Phase Trials
Completed 28
Not yet recruiting 9
Terminated 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Casodex

Sponsor Name

Sponsor Name for Casodex
Sponsor Trials
AstraZeneca 13
National Cancer Institute (NCI) 7
M.D. Anderson Cancer Center 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Casodex
Sponsor Trials
Other 37
Industry 33
NIH 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Dow
Mallinckrodt
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.